Experience

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…

Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc…

Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…

Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…

Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…